Clinical Trial Update: Study of Nanoliposomal Irinotecan (Nal-IRI)-Containing Regimens Versus Nab-paclitaxel Plus Gemcitabine in Patients With Previously Untreated, Metastatic Pancreatic Adenocarcinoma [Phase 2]

View source ↗

Summary

Phase 2 trial comparing Nanoliposomal Irinotecan (Nal-IRI)–containing regimens to nab-paclitaxel plus gemcitabine in previously untreated metastatic pancreatic …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Cancer

Drugs mentioned

• Gemcitabine (Gemcitabine)
• Nab-paclitaxel (paclitaxel protein-bound)
• Nanoliposomal irinotecan (Nal-IRI) (irinotecan liposome)

Snippet

Sponsor: Ipsen | Conditions: Pancreatic Cancer | Phase 2 | Status: COMPLETED | Results posted: 2022-10-10